Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...
South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...
Zimbabwe is among 10 nations rolling out lenacapavir, a twice-yearly HIV prevention shot. Experts call it a breakthrough but ...
The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...
Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, ...
Pre-exposure prophylaxis (PrEP) is a daily pill taken by HIV-negative people to prevent HIV infection. It can also be taken on demand before and after sex. The medicine stops the virus from getting ...
8hon MSNOpinion
HIV rates highest in the American South, despite effective treatments: A clash between culture and public health
The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in ...
The Adamawa State Agency for the Control of AIDS (ADSACA) has reported 8,850 new HIV infections in the state between 2022 and ...
Lesotho reached a milestone late last year — UNAIDS’s 95-95-95 goal, with 95% of people living with HIV aware of their status ...
Community advocates, health providers and local leaders in Charleston are all joining forces Wednesday in observance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback